Umar Badar Uddin, Rahman Sayeeda, Dutta Siddhartha, Islam Tariqul, Nusrat Nadia, Chowdhury Kona, Binti Wan Ahmad Fakuradzi Wan Farizatul Shima, Haque Mainul
Medical Education, Oxford College of Arts, Business and Technology, Toronto, CAN.
School of Medicine, American University of Integrative Sciences, Bridgetown, BRB.
Cureus. 2022 Aug 18;14(8):e28130. doi: 10.7759/cureus.28130. eCollection 2022 Aug.
Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally. The principal therapeutic intervention for AD is long-standing topical glucocorticoids, which have been used for several decades. Corticosteroid therapy brings several adverse drug effects (ADRs), including irreversible skin atrophy. Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD.
特应性皮炎(AD)是一种持久的炎症性皮肤病,其特征为瘙痒、湿疹样、稀疏的小水泡,内含清澈的水样物质。此外,患病皮肤可能会化脓,偶尔会有渗液,并伴有受累皮肤增厚。这被认为是全球涉及儿童和成人人群的最常见皮肤疾病之一。AD的主要治疗干预措施是长期使用外用糖皮质激素,这种药物已经使用了几十年。皮质类固醇治疗会带来多种药物不良反应(ADR),包括不可逆的皮肤萎缩。他克莫司属于钙调神经磷酸酶抑制剂类,是一种在治疗AD方面具有显著疗效的免疫调节剂。外用他克莫司是一种治疗AD的有效且安全的非皮质类固醇替代疗法。我们回顾了现有文献,以比较并确立他克莫司与皮质类固醇疗法在治疗AD时的安全性、疗效和有效性。